301 related articles for article (PubMed ID: 38433233)
1. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
2. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
3. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
5. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial interventions for cannabis use disorder.
Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
[TBL] [Abstract][Full Text] [Related]
7. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap.
Cleirec G; Desmier E; Lacatus C; Lesgourgues S; Braun A; Peloso C; Obadia C
Front Psychiatry; 2022; 13():899221. PubMed ID: 35686188
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
Freeman TP; Hindocha C; Baio G; Shaban NDC; Thomas EM; Astbury D; Freeman AM; Lees R; Craft S; Morrison PD; Bloomfield MAP; O'Ryan D; Kinghorn J; Morgan CJA; Mofeez A; Curran HV
Lancet Psychiatry; 2020 Oct; 7(10):865-874. PubMed ID: 32735782
[TBL] [Abstract][Full Text] [Related]
11. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder.
Hua DY; Hindocha C; Baio G; Lees R; Shaban N; Morgan CJ; Mofeez A; Curran HV; Freeman TP
Transl Psychiatry; 2023 Apr; 13(1):131. PubMed ID: 37085531
[TBL] [Abstract][Full Text] [Related]
12. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
13. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
[TBL] [Abstract][Full Text] [Related]
14. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial.
Efron D; Taylor K; Payne JM; Freeman JL; Cranswick N; Mulraney M; Prakash C; Lee KJ; Williams K
BMJ Open; 2020 Mar; 10(3):e034362. PubMed ID: 32152170
[TBL] [Abstract][Full Text] [Related]
15. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
16. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
Rømer Thomsen K; Thylstrup B; Kenyon EA; Lees R; Baandrup L; Feldstein Ewing SW; Freeman TP
Neurosci Biobehav Rev; 2022 Jan; 132():169-180. PubMed ID: 34822876
[TBL] [Abstract][Full Text] [Related]
18. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
[TBL] [Abstract][Full Text] [Related]
19. Cannabis and schizophrenia.
McLoughlin BC; Pushpa-Rajah JA; Gillies D; Rathbone J; Variend H; Kalakouti E; Kyprianou K
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004837. PubMed ID: 25314586
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
